Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CytomX

This page shows the latest CytomX news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs. Stellar valuations for immuno-oncology candidates continue. ... Shares in US clinical stage biopharmaceutical company CytomX leaped more than a third on the latest deal.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    BMS has expanded its 2014 agreement with CytomX Therapeutics to access up to eight further targets in oncology and other fields, using CytomX’s Probody platform. ... 650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... Zymeworks, like CytomX, have multiple Big Pharma partners including Merck &Co and Lilly.

  • Pharma deals during May 2014 Pharma deals during May 2014

    BMS also entered into a platform deal with CytomX for so-called “ Probodies,” monoclonal antibodies that are selectively activated within the cancer microenvironment.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    CytomX / BMS. Development and commercialisation licence. Selective monoclonal antibodies (“ Probodies”) for up to 4 oncology targets.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    818. CytomX / Pfizer. Collaboration and exclusive licence to selected PDCs.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    CytomX appoints Rachel Humphrey chief medical officer. Former VP of Eli Lilly and AstraZeneca joins the company. ... She said: “ Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... His new colleague Ray joined CytomX in 2011 and was instrumental in brokering the agreement with Pfizer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia